Jafron Biomedical Co

Jafron Biomedical Co P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Jafron Biomedical Co (300529.SZ) as of Oct 16, 2026 is 28.74. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 19.32 — a change of 48.71% (higher).

P/FCF

28.74

YoY

48.71%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Jafron Biomedical Co is 2025 28.74 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Jafron Biomedical Co was 2024 19.32 . It decreases by 48.71% higher compared to the previous year.

The Jafron Biomedical Co P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
74.88 CNY
Jan 1, 2019
43.45 CNY
Jan 1, 2020
26.26 CNY
Jan 1, 2021
22.14 CNY
Jan 1, 2022
38.65 CNY
Jan 1, 2023
23.55 CNY
Jan 1, 2024
19.32 CNY
Jan 1, 2025
28.74 CNY
The Jafron Biomedical Co P/FCF history
YEARP/FCFYoY
28.74+48.71%
19.32-17.94%
23.55-39.07%
38.65+74.55%
22.14-15.68%
26.26-39.57%
43.45-41.97%
74.88-39.98%
124.76+18.69%
105.11-4.14%
109.65-49.18%
215.77—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co Ltd is a China-based health care company headquartered in Zhuhai. The company focuses on the research, development, production, and sale of hemoperfusion products. It went public on August 2, 2016, with its stock listed under ticker 300529.SZ and ISIN CNE100002995. Jafron employs 3,003 full-time staff and operates within the health care sector. Its products include disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resin bandages. These products are used in treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. Jafron's products are distributed across more than 3,000 hospitals in all 31 provinces of China. The company's website is https://www.jafron.com/. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Jafron Biomedical Co is 28.74 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Jafron Biomedical Co changed from 19.32 to 28.74, representing a 48.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Jafron Biomedical Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Jafron Biomedical Co